Methotrexate Biodim (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into tetrahydrofolate. This interruption limits the production of nucleotides needed for DNA and RNA synthesis, leading to reduced replication of rapidly dividing cells such as immune cells and cancer cells.

The dosing schedule for Methotrexate Biodim is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Healthcare providers determine the appropriate dose, frequency, and route of administration.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of childbearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug may be excreted in milk, so use is generally avoided.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Methotrexate is a folate antagonist, similar to drugs like pemetrexed, but it is distinguished by its broad therapeutic range, including autoimmune diseases and multiple cancers. Compared with newer biologics, methotrexate is less expensive but requires careful monitoring for toxicity.

Methotrexate Biodim should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

The product is supplied as a sterile solution for injection and can be given via intra‑arterial, intramuscular, or intrathecal routes, depending on the clinical indication and physician’s judgment. Administration is performed by qualified healthcare professionals under aseptic conditions.

Serious risks include myelosuppression leading to severe infection or bleeding, hepatotoxicity that may progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be monitored regularly for these complications.

Methotrexate Biodim is contraindicated in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, and in pregnant women. Caution is also advised for individuals with pre‑existing blood dyscrasias or pulmonary disease.